Code | Accounting Metric | 2021 Response | |
Safety of Clinical Trial Participants | |||
HC-BP-210a.1 | Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials | Biogen has a Global Pharmacovigilance (PV) team comprised of medical and scientific professionals with extensive safety and/or clinical or healthcare experience who are trained in PV and worldwide health authority regulations relevant to medicinal product safety. Biogen’s safety signal management processes, combined with our robust safety governance framework, allow Biogen to determine if new safety information on our products (a “signal”) poses a risk to patients and how best to manage, mitigate and communicate the risk. All safety and benefit/risk decisions for marketed and investigational products are made at the Safety Monitoring Committee (SMC). The Safety team collaborates with Regulatory Affairs to communicate product information in a timely, transparent and accurate manner to regulatory agencies across the globe. In addition to complying with our company’s global standards, the conduct of our clinical trials adheres to the International Council for Harmonization Good Clinical Practice (ICH GCP) standards and to the principles that have their origin in the Declaration of Helsinki. Each country has its own regulatory authority with its own regulations, or laws, for conducting a clinical trial. The regulatory authority reviews and approves the protocol and ensures that the clinical trial follows national regulations. An Institutional Review Board (IRB) or Ethics Committee (EC) is an independent committee that includes medical, scientific and non-scientific members, whose responsibility is to protect the rights, welfare, safety and well-being of clinical trial participants. Each clinical trial location is monitored by a specific IRB / EC. It is responsible for reviewing all clinical trials as well as conducting ongoing reviews of active clinical trials. For more information, please visit our clinical trials page. | |
HC-BP-210a.2 | Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) | Biogen is committed to collaborating with regulatory agencies on a wide range of issues, including clinical trial management and pharmacovigilance and taking any actions that are needed. Please see Biogen's 2021 Annual Report for any relevant disclosures. | |
HC-BP-210a.3 | Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries | Biogen did not sustain any monetary losses in 2021 as a result of legal proceedings associated with clinical trials in developing countries. Biogen discloses all material legal and regulatory proceedings in our 2021 Annual Report and Quarterly Reports on Form 10-Q. | |
Access to Medicines | |||
HC-BP-240a.1 | Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index | While not listed as a company in scope for the 2022 Access to Medicine Index ("Index"), Biogen is deeply committed to health access and equity across our business. We are expanding our portfolio and pipeline, which includes a focus on diseases and conditions prioritized by the Index, including Alzheimer's disease, depression and stroke. Additionally, Biogen therapies support patients in a number of countries included in the Index, such as Brazil, China, India, and Mexico, and we actively work with a variety of stakeholders to understand opportunities to meet patient needs. For example, in India, we advanced our SPINRAZA Individual Patient Humanitarian Aid Access Program (SIPHAP) to a total of 211 patients across 14 public hospitals in 2021. In India and in other markets we serve, we are continuing to explore opportunities and advance programs that promote health access. For additional detail on this and other programs designed to promote health access and equity, please see the Patients section of Biogen’s 2021 Year In Review. | |
HC-BP-240a.2 | List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) | Biogen has no products on the WHO List of Prequalified Medicinal Products. | |
Affordability & Pricing | |||
HC-BP-240b.1 | Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period | Biogen does not comment on confidential legal matters. | |
HC-BP-240b.2 | Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year | In 2021, we saw a list price increase of 3.805% and a net price decrease of 4.324% across our U.S. product portfolio compared to the previous year. In addition, Biogen’s anti-TNF biosimilars may have provided healthcare savings of approximately €2.6 billion in 2021 in the markets where they are sold. These savings may provide headroom for new innovative therapies to come to market. We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here: | |
HC-BP-240b.3 | Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year | We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and patient advocacy organizations and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here: | |
Drug Safety | |||
HC-BP-250a.1 | List of products listed in the U.S. Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database | There were no listings relevant to Biogen’s products on the FDA’s MedWatch Safety Alerts for Human Medical Products database in 2021. | |
HC-BP-250a.2 | Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System | All information related to fatalities associated with Biogen products are available via the FDA Adverse Event Reporting System. | |
HC-BP-250a.3 | Number of recalls issued, total units recalled | A Class II VUMERITY recall that was initiated in December 2020 was closed in September 2021. For any relevant disclosures, please see Biogen’s 2021 Annual Report. | |
HC-BP-250a.4 | Total amount of product accepted for take-back, reuse, or disposal | Biogen does not track the amount of product accepted for takeback, reuse or disposal; the volume of Biogen products is too low to warrant managing our own product takeback, reuse or disposal program. Biogen does, however, participate in several takeback programs across various U.S. states and counties, and several other countries. In addition, Biogen provides guidance on appropriate disposal methods for our products. | |
HC-BP-250a.5 | Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type | Biogen did not receive any FDA enforcement actions associated with Form 483 observations, warning letters, seizures, recalls or consent decrees in 2021. | |
Counterfeit Drugs | |||
HC-BP-260a.1 | Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting | Counterfeiting is now the largest criminal enterprise in the world, accounting for more than 3% of global trade. Not one industry is exempt from this growing threat. Patient safety is our number one priority and we take the issue of counterfeit, falsified drugs very seriously. The main goal of our Product Security function is to implement a holistic strategy in order to proactively identify, mitigate and manage illicit trade risks that could be impacting reputation and trust, and most importantly jeopardizing the health and safety of patients who take our drugs. We aim to disrupt diversion, counterfeiting, theft and other nefarious activities through the following five pillars:
|
|
HC-BP-260a.2 | Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products | Biogen employs quality governed processes to manage the handling of suspect or illegitimate medicinal products: Upon detecting a potential or known product security risk, the event is captured as a complaint into the TrackWise system for formal tracking. Furthermore, there are requirements on segregation of product and the investigation process. Once the product is physically acquired, the technical product complaints group performs an investigation to verify if the product is genuine or falsified. If determined that the suspected product is falsified, potentially falsified or high risk of being falsified, a DMRB (global distributed material review board) must be completed, defining further specific market actions and communications. As necessary, all impacted competent authorities and impacted distribution partners are then notified. Once a case is closed, Biogen notifies the applicable authorities and impacted trading partners. In addition to the above internal processes, Biogen also participates in industry-wide systems and processes utilizing serialization data. For example, in the EU each medication is verified against the list of serial numbers in circulation, prior to dispensing. Medicines shall not be dispensed if the number cannot be verified. If a medicine’s serial number cannot be verified, a notification, called an alert, is electronically generated by the relevant National Medicines Verification Organization (NMVO) and shared with TraceLink, Biogen’s Serialization System. Biogen reviews these alerts and resolves them in correspondence with the relevant NMVO. Serialization alerts that indicate suspect or illegitimate product will trigger the internal process described above. | |
HC-BP-260a.3 | Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products | Biogen did not take any actions in 2021 that led to raids, seizures, arrests and/or filing of criminal charges related to counterfeit products. | |
Ethical Marketing | |||
HC-BP-270a.1 | Total amount of monetary losses as a result of legal proceedings associated with false marketing claims | Biogen did not sustain any monetary losses in 2021 as a result of legal proceedings associated with false marketing claims. Biogen discloses all material legal and regulatory proceedings in our 2021 Annual Report and Quarterly Reports on Form 10-Q. | |
HC-BP-270a.2 | Description of codes of ethics governing promotion of off-label use of products | Please visit our Early Access page. | |
Employee Recruitment, Developing & Retention | |||
HC-BP-330a.1 | Discussion of talent recruitment and retention efforts for scientists and research and development personnel | Biogen has a range of active initiatives to help build a diverse talent pipeline. For example, the Biogen Community Lab is the longest-running hands-on corporate science education program in the U.S., and now reaches students in more than 19 countries. Collaborations with Massachusetts General Hospital and Duke University are giving the next generation in-depth exposure to the field of neurology. Through a collaboration with Morehouse School of Medicine, we welcomed our first intern cohort from Historically Black Colleges and Universities (HBCUs) to our Summer Health Equity Fellowship Program in 2020. The fellowship program, which engages M.D. and Ph.D. students, aims to advance health equity and improve patient experiences. In 2021, we increased overall participation from 5 to 18 interns, falling just shy of our goal to increase participation by 300% from our 2020 number. In 2016, Biogen helped create The Partnership Inc.’s BioDiversity Fellows Program, which nurtures the potential leadership of mid-career professionals who are underrepresented in the life sciences industry. In Latin America, the Biogen Intercontinental Region (BIR) developed FemSTEM, a campaign to empower girls and women to pursue a path in STEM. The campaign includes a podcast series and opportunities for participants to engage via Women in Bio, UN Women and NS Innovation in South America. Biogen employees volunteer in Women in Bio. We remain actively involved in a wide variety of industry programs that allow us to increase the visibility of Biogen as a purpose-driven company with a wide variety of career opportunities and a culture focused on helping employees thrive. We have a particular focus on increasing visibility and engagement with communities historically underrepresented and underserved in neuroscience, including through our engagement with groups such as Women of Color in Pharma (WOCIP) and American Women in Science (AWIS), among many others. We also have continued to expand our focus on talent retention, growth and engagement through programs such as Thrive@Biogen. A broader discussion of those efforts can be found in the Our People section of the 2021 Year In Review. | |
HC-BP-330a.2 | (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid level managers, (c) professionals, and (d) all others | Total Turnover Rate: 14% Voluntary Turnover Rate: 11% Involuntary Turnover Rate: 3% Please see disclosures in Biogen’s 2021 ESG Data Table. |
|
Supply Chain Management | |||
HC-BP-430a.1 | Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients | Biogen outsources anywhere from 10% to 15% of our external supplier audits. We perform the vast majority of our audits through our own audit program using outsourced support or the use of third-party auditors depending on the type of service provided, risk and availability. | |
Business Ethics | |||
HC-BP-510a.1 | Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery | Biogen did not sustain any monetary losses in 2021 as a result of legal proceedings associated with corruption, bribery or anti-competitive behaviors. Biogen discloses all material legal and regulatory proceedings in our 2021 Annual Report and Quarterly Reports on Form 10-Q. | |
HC-BP-510a.2 | Description of code of ethics governing interactions with healthcare professionals | We comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) Code on Interactions with Healthcare Professionals. See our Code of Business Conduct section on Interactions with Healthcare Professionals. | |
Business Ethics | |||
HC-BP-000.A | Number of patients treated | Biogen has treated more than 2 million patients worldwide from 1996 through the end of 2021. Additionally, we have approximately 30 clinical programs across a broad set of disease areas. | |
HC-BP-000.B | Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3) | As of report publication, Biogen has 10 marketed therapies, as outlined on the Product Portfolio page of Biogen.com and approximately 30 therapies in the pipeline. | |
GRI Indicator | Description | Reference | SDG Alignment |
GRI 102: GENERAL DISCLOSURES | |||
Organizational Profile | |||
102-1 | Name of the organization | Biogen Inc. | |
102-2 |
|
CEO Letter – 2021 Year in Review Item 1., Business, 2021 Annual Report |
|
102-3 | Location of headquarters | Corporate Headquarters: Cambridge, Massachusetts (U.S.) | |
102-4 | Number of countries where the organization operates, and the names of countries where it has significant operations and/or that are relevant to the topics covered in the report. | Pharmaceutical Operations & Technology Item 2., Properties, 2021 Annual Report |
|
102-5 | Nature of ownership and legal form. | Board of Directors Corporate Governance Documents |
|
102-6 | Markets served, including:
|
Item 1., Business, 2021 Annual Report | |
102-7 | Scale of the organization, including:
|
2021 Annual Report Item 1., Business, 2021 Annual Report Item 6., Selected Financial Data, 2021 Annual Report ESG Data Table – 2021 Year in Review |
|
102-8 |
|
Item 1., Business, 2020 Form 10-K ESG Data Table – 2021 Year in Review |
|
102-9 | A description of the organization’s supply chain, including its main elements as they relate to the organization’s activities, primary brands, products and services. | Item 1., Business, 2021 Annual Report | 12 |
102-10 | Significant changes to the organization’s size, structure, ownership, or supply chain, including:
|
Item 1., Business, 2021 Annual Report | |
102-11 | Whether and how the organization applies the Precautionary Principle or approach. | Biogen applies the Precautionary Principle through a variety of environment, health and safety (EHS) and risk management policies and programs designed to ensure the safety of products, patients, employees and the environment. Details are available in Form 10-K and on Biogen.com. | |
102-12 | A list of externally developed economic, environmental and social charters, principles or other initiatives to which the organization subscribes, or which it endorses. | Principles, Policies and Positions Code of Business Conduct All major charters, principles or other initiatives are included in the boundaries of this report. |
|
102-13 | A list of the main memberships of industry or other associations, and national or international advocacy organizations. | Community and Reporting – 2021 Year in Review | |
Strategy | |||
102-14 | A statement from the most senior decision-maker of the organization (such as CEO, chair, or equivalent senior position) about the relevance of sustainability to the organization and its strategy for addressing sustainability. | CEO Letter – 2021 Year in Review | |
102-15 | A description of key impacts, risks and opportunities. | Item 1A., Risk Factors, 2021 Annual Report TCFD Report – 2021 Year in Review* |
|
Ethics and Integrity | |||
102-16 | A description of the organization’s values, principles, standards and norms of behavior. | Principles, Policies and Positions Code of Business Conduct Our Purpose – 2021 Year in Review |
|
102-17 | A description of internal and external mechanisms for:
|
Code of Business Conduct* | |
Governance | |||
102-18 |
|
Executive Leadership Board of Directors Corporate Governance Documents ESG Data Table – 2021 Year in Review |
|
102-21 |
|
Executive Leadership Board of Directors Corporate Governance Documents Reporting – 2021 Year in Review [Materiality Assessment]* |
|
102-22 | a. Composition of the highest governance body and its committees by:
|
Item 1., Business, 2020 Form 10-K ESG Data Table – 2021 Year in Review* |
|
102-26 | Highest governance body’s and senior executives’ roles in the development, approval and updating of the organization’s purpose, value or mission statements, strategies, policies and goals related to economic, environmental and social topics. | Our Purpose – 2021 Year in Review* | |
102-30 | Highest governance body’s role in reviewing the effectiveness of the organization’s risk management processes for economic, environmental and social topics. | Code of Business Conduc Sustainability Policy Environmental Health and Safety Policy Climate Change Position |
|
102-33 | Process for communicating critical concerns to the highest governance body. | Code of Business Conduct | |
Stakeholder Engagement | |||
102-40 | A list of stakeholder groups engaged by the organization. | 2021 Annual Report Item 1., Business, 2021 Annual Report Executive Leadership |
|
102-41 | Percentage of total employees covered by collective bargaining agreements. | Approximately 13.1% of Biogen’s employees are under a collective bargaining agreement using a time-weighted average basis. | |
102-42 | The basis for identifying and selecting stakeholders with whom to engage. | Executive Leadership Board of Directors Corporate Governance Documents ESG Data Table – 2021 Year in Review Reporting – 2021 Year in Review |
|
102-43 | The organization’s approach to stakeholder engagement, including frequency of engagement by type and by stakeholder group, and an indication of whether any of the engagement was undertaken specifically as part of the report preparation process. | Executive Leadership Board of Directors Corporate Governance Documents ESG Data Table – 2021 Year in Review* |
|
102-44 | Key topics and concerns that have been raised through stakeholder engagement, including:
|
Patients and Reporting – 2021 Year in Review | |
Reporting Practice | |||
102-45 |
|
Item 1., Business, 2021 Annual Report All major entities are included in the boundaries of this report. |
|
102-46 |
|
Reporting – 2021 Year in Review | |
102-47 | A list of the material topics identified in the process for defining report content. | Reporting – 2021 Year in Review | |
102-48 | The effect of any restatements of information given in previous reports, and the reasons for such restatements. | Restatements for previous disclosed metrics are identified in the ESG Data Table. | |
102-49 | Significant changes from previous reporting periods in the list of material topics and topic Boundaries. | Biogen conducted an ESG materiality assessment in 2021. The results inform the topic boundaries of this report and can be found in the Reporting section of this 2021 Year in Review. | |
102-50 | Reporting period for the information provided. | Data cover fiscal year ending Dec. 31, 2021 (Some activities from 2022 are also included.) | |
102-51 | If applicable, the date of the most recent previous report. | April 23, 2021 | |
102-52 | Reporting cycle. | We report on an annual basis | |
102-53 | The contact point for questions regarding the report or its contents. | Responsibility contact: responsibility@biogen.com | |
102-54 | The claim made by the organization, if it has prepared a report in accordance with the GRI Standards, either: • ’This report has been prepared in accordance with the GRI Standards: Core option’. • ’This report has been prepared in accordance with the GRI Standards: Comprehensive option’. | This report has been prepared in accordance with the GRI Standards: Core option/Alignment option. | |
102-55 |
|
GRI Content Index | |
102-56 |
|
Independent Assurance Statement to Biogen Inc. | |
GRI 103 MANAGEMENT APPROACH | |||
103-1 |
|
Reporting – 2021 Year in Review [Materiality assessment] | |
103-2 |
|
Principles, Policies and Positions Code of Business Conduct Our Purpose – 2021 Year in Review Reporting – 2021 Year in Review [Materiality assessment] |
|
103-3 | An explanation of how the organization evaluates the management approach, including:
|
Consolidated Financial Statements Item 1., Business, 2021 Annual Report Independent Assurance Statement to Biogen Inc. Reporting – 2021 Year in Review [Materiality assessment] |
|
GRI 200 ECONOMIC | |||
201 Economic Performance | |||
201-1 |
|
Item 6., Selected Financial Data, 2021 Annual Report Political Contribution Disclosures ESG Data Table – 2021 Year in Review* |
|
201-2 | Risks and opportunities posed by climate change that have the potential to generate substantive changes in operations, revenue or expenditure, including:
2.2 When compiling the information specified in Disclosure 201-2, if the reporting organization does not have a system in place to calculate the financial implications or costs, or to make revenue projections, it shall report its plans and timeline to develop the necessary systems. |
TCFD Report – 2021 Year in Review 2021 CDP Climate Change disclosure |
|
201-3 |
|
Consolidated Financial Statements Item 1., Business, 2021 Annual Report |
|
201-4 |
2.5 When compiling the information specified in Disclosure 201–4, the reporting organization shall identify the monetary value of financial assistance received from government through consistent application of generally accepted accounting principles. |
Consolidated Financial Statements Item 1., Business, 2021 Annual Report* |
|
203 Indirect Economic Impacts | |||
203-2 |
|
2021 Annual Report Reporting – 2021 Year in Review |
3, 4, 8 |
204 Procurement Practices | |||
204-1 |
|
Biogen discloses this information only on a global level. Principles, Policies & Positions Supplier Diversity – Working With Us Pioneering Science – 2021 Year in Review |
5, 8 |
205 Anti-Corruption | |||
205-3 |
|
ESG Data Table – 2021 Year in Review* | |
207 Tax | |||
207-1 | A description of the approach to tax, including:
|
Biogen Global Tax Policy | |
GRI 300 ENVIRONMENTAL | |||
302 Energy | |||
302-1 | The reporting organization shall report the following information:
|
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review |
12 |
302-3 |
2.5 When compiling the information specified in Disclosure 302–3, the reporting organization shall: 2.5.1 Calculate the ratio by dividing the absolute energy consumption (the numerator) by the organization-specific metric (the denominator). 2.5.2 If reporting an intensity ratio both for the energy consumed within the organization and outside of it, report these intensity ratios separately. |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Energy disclosure |
|
303 Water and Effluents | |||
303-1 |
|
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Water Security disclosure |
6 |
303-2 | A description of any minimum standards set for the quality of effluent discharge, and how these minimum standards were determined, including:
|
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Water Security disclosure |
6 |
303-3 |
2.1 When compiling the information specified in Disclosure 303–3, the reporting organization shall use publicly available and credible tools and methodologies for assessing water stress in an area. |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review |
6 |
303-4 |
|
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Water Security disclosure |
6 |
303-5 |
|
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Water Security disclosure |
6 |
305 Emissions | |||
305-1 |
2.1 When compiling the information specified in Disclosure 305-1, the reporting organization shall: 2.1.1 Exclude any GHG trades from the calculation of gross direct (Scope 1) GHG emissions. 2.1.2 Report biogenic emissions of CO2 from the combustion or biodegradation of biomass separately from the gross direct (Scope 1) GHG emissions. Exclude biogenic emissions of other types of GHG (such as CH4 and N2O), and biogenic emissions of CO2 that occur in the life cycle of biomass other than from combustion or biodegradation (such as GHG emissions from processing or transporting biomass). |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Climate Change disclosure* |
7,13 |
305-2 |
2.3 When compiling the information specified in Disclosure 305–2, the reporting organization shall: 2.3.1 Exclude any GHG trades from the calculation of gross energy indirect (Scope 2) GHG emissions. 2.3.2 Exclude other indirect (Scope 3) GHG emissions that are disclosed as specified in Disclosure 305–3. 2.3.3 Account and report energy indirect (Scope 2) GHG emissions based on the location-based method, if it has operations in markets without product or supplier-specific data. 2.3.4 Account and report energy indirect (Scope 2) GHG emissions based on both the location-based and market-based methods, if it has any operations in markets providing product or supplier-specific data in the form of contractual instruments. |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Climate Change disclosure* |
7,13 |
305-3 |
2.5 When compiling the information specified in Disclosure 305–3, the reporting organization shall: 2.5.1 Exclude any GHG trades from the calculation of gross other indirect (Scope 3) GHG emissions. 2.5.2 Exclude energy indirect (Scope 2) GHG emissions from this disclosure. Energy indirect (Scope 2) GHG emissions are disclosed as specified in Disclosure 305–2. 2.5.3 Report biogenic emissions of CO2 from the combustion or biodegradation of biomass that occurs in its value chain separately from the gross other indirect (Scope 3) GHG emissions. Exclude biogenic emissions of other types of GHG (such as CH4 and N2O), and biogenic emissions of CO2 that occur in the life cycle of biomass other than from combustion or biodegradation (such as GHG emissions from processing or transporting biomass). |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review 2021 CDP Climate Change disclosure* |
7,13 |
305-5 |
2.9 When compiling the information specified in Disclosure 305–5, the reporting organization shall: 2.9.1 Exclude reductions resulting from reduced production capacity or outsourcing. 2.9.2 Use the inventory or project method to account for reductions. 2.9.3 Calculate an initiative’s total reductions of GHG emissions as the sum of its associated primary effects and any significant secondary effects. 2.9.4 If reporting two or more Scope types, report the reductions for each separately. 2.9.5 Report reductions from offsets separately. |
Environment – 2021 Year in Review 2021 CDP Climate Change disclosure |
7,13 |
305-7 |
2.13 When compiling the information specified in Disclosure 305-7, the reporting organization shall select one of the following approaches for calculating significant air emissions: 2.13.1 Direct measurement of emissions (such as online analyzers). 2.13.2 Calculation based on site-specific data. 2.13.3 Calculation based on published emission factors. 2.13.4 Estimation. If estimations are used due to a lack of default figures, the organization shall indicate the basis on which figures were estimated. |
Environment – 2021 Year in Review ESG Data Table – 2021 Year in Review |
7,13 |
306 Waste | |||
306-1 | For the organization’s significant actual and potential waste-related impacts, a description of:
|
Environment – 2021 Year in Review | 12 |
306-2 |
|
Environment – 2021 Year in Review | 12 |
306-3 |
2.1 When compiling the information specified in Disclosure 306-3-a, the reporting organization shall: 2.1.1 Exclude effluent, unless required by national legislation to be reported under total waste. 2.1.2 Use 1,000 kilograms as the measure for a metric ton. |
Environment – 2021 Year in Review | 12 |
307 Environmental Compliance | |||
307-1 |
|
There were no significant instances of non-compliance in 2021. Principles, Policies & Positions Item 1A., Risk Factors, 2021 Annual Report |
12 |
308 Supplier Environmental Assessments | |||
308-1 | Percentage of new suppliers that were screened using environmental criteria. | Environment – 2021 Year in Review | 12 |
308-2 | Negative environmental impacts in the supply chain and actions taken
|
Item 1A., Risk Factors, 2021 Annual Report Environment – 2021 Year in Review Reporting – 2021 Year in Review |
12 |
GRI 400 SOCIAL | |||
401 Employment | |||
401-1 |
|
Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review SASB Content Index – 2021 Year in Review* |
|
403 Occupational Health and Safety | |||
403-1 |
|
Corporate Responsibility Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review |
3, 8 |
403-2 |
|
Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review |
|
403-3 | A description of the occupational health services’ functions that contribute to the identification and elimination of hazards and minimization of risks, and an explanation of how the organization ensures the quality of these services and facilitates workers’ access to them. | Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review |
|
403-4 | The reporting organization shall report the following information for employees and for workers who are not employees but whose work and/or workplace is controlled by the organization:
|
Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review |
|
403-5 | A description of any occupational health and safety training provided to workers, including generic training as well as training on specific work-related hazards, hazardous activities, or hazardous situations. | Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review |
|
403-6 |
|
Our People – 2021 Year in Review* | |
403-7 | A description of the organization’s approach to preventing or mitigating significant negative occupational health and safety impacts that are directly linked to its operations, products or services by its business relationships, and the related hazards and risks. | Our People – 2021 Year in Review | |
403-9 |
2.1 When compiling the information specified in Disclosure 403–9, the reporting organization shall: 2.1.1 Exclude fatalities in the calculation of the number and rate of high-consequence work-related injuries. 2.1.2 Include fatalities as a result of work-related injury in the calculation of the number and rate of recordable work-related injuries. 2.1.3 Include injuries as a result of commuting incidents only where the transport has been organized by the organization. 2.1.4 Calculate the rates based on either 200,000 or 1,000,000 hours worked, using the following formulas: Refer to standard 403. |
Environmental, Health and Safety Policy Statement Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review |
3, 8 |
404 Training and Education | |||
404-1 | Average hours of training that the organization’s employees have undertaken during the reporting period, by:
|
Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review |
|
404-2 |
|
Our People – 2021 Year in Review | |
404-3 | Percentage of total employees by gender and by employee category who received a regular performance and career development review during the reporting period. | Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review |
|
405 Diversity and Equal Opportunity | |||
405-1 |
|
Item 1., Business, 2021 Annual Report* Board of Directors Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review* |
5 |
405-2 |
|
Biogen does not disclose externally any salary-and wages-related data except the Executive Compensation of the Executive Committee and Board of Directors. Our People – 2021 Year in Review ESG Data Table – 2021 Year in Review* |
5 |
406 Non-Discrimination | |||
406-1 |
2.1 When compiling the information specified in Disclosure 406–1, the reporting organization shall include incidents of discrimination on grounds of race, color, sex, religion, political opinion, national extraction or social origin as defined by the ILO, or other relevant forms of discrimination involving internal and/or external stakeholders across operations in the reporting period. |
Our People – 2021 Year in Review | |
413 Local Communities | |||
413-1 | Percentage of operations with implemented local community engagement, impact assessments and/or development programs, including the use of:
|
Grants Management and Strategic Giving Patients and Community – 2021 Year in Review |
3, 4 |
414 Supplier Social Assessment | |||
414-1 | Percentage of new suppliers that were screened using social criteria. | Code of Business Conduct Supplier Diversity – Working With Us Pioneering Science and Reporting – 2021 Year in Review |
5, 8, 12 |
414-2 |
|
Code of Business Conduct Supplier Diversity – Working With Us Pioneering Science and Reporting – 2021 Year in Review ESG Data Table – 2021 Year in Review |
5, 8, 12 |
415 Public Policy | |||
415-1 |
2.1 When compiling the information specified in Disclosure 415–1, the reporting organization shall calculate financial political contributions in compliance with national accounting rules, where these exist. |
Political Contributions, Disclosures Community – 2021 Year in Review |
16 |
416 Customer Health and Safety | |||
416-1 | Percentage of significant product and service categories for which health and safety impacts are assessed for improvement. | Principles, Policies & Positions Patient Safety Environment, Product Stewardship Pioneering Science and Patients – 2021 Year in Review |
3 |
416-2 |
2.1 When compiling the information specified in Disclosure 416–2, the reporting organization shall: 2.1.1 Exclude incidents of non-compliance in which the organization was determined not to be at fault. 2.1.2 Exclude incidents of non-compliance related to labeling. Incidents related to labeling are reported in Disclosure 417–2 of GRI 417: Marketing and Labeling. 2.1.3 If applicable, identify any incidents of non-compliance that relate to events in periods prior to the reporting period. |
Patient Safety Pioneering Science – 2021 Year in Review ESG Data Table – 2021 Year in Review |
3 |
417 Marketing and Labeling | |||
417-1 |
|
Principles, Policies & Positions Patient Safety Pioneering Science, Patients and Environment – 2021 Year in Review |
3, 16 |
417-2 |
2.1 When compiling the information specified in Disclosure 417-2, the reporting organization shall: 2.1.1 Exclude incidents of non-compliance in which the organization was determined not to be at fault. 2.1.2 If applicable, identify any incidents of non-compliance that relate to events in periods prior to the reporting period. |
There were no significant instances of non-compliance in 2021. Principles, Policies & Positions |
3 |
417-3 |
2.2 When compiling the information specified in Disclosure 417–3, the reporting organization shall: 2.2.1 Exclude incidents of non-compliance in which the organization was determined not to be at fault. 2.2.2 If applicable, identify any incidents of non-compliance that relate to events in periods prior to the reporting period. |
There were no significant instances of non-compliance in 2021. Principles, Policies & Positions |
3 |